Thank you for joining us for the Cigna Group's Fourth Quarter 2023 Results Review. Please note that this conference, including the Q&A session, is being recorded. We'll now turn the conference over to Ralph Giacobbe. Please proceed.

Great. Thanks, operator. Good morning, everyone. Thank you for joining today's call. I'm Ralph Giacobbe, Senior Vice President of Investor Relations. With me on the line this morning are David Cordani, The Cigna Group's Chairman and Chief Executive Officer; Brian Evanko, Chief Financial Officer of the Cigna Group and President and Chief Executive Officer of Cigna Healthcare; and Eric Palmer, President and Chief Executive Officer of Evernorth Health Services. In our remarks today, David and Brian will cover a number of topics including our fourth quarter and full year 2023 financial results and our financial outlook for 2024. Following their prepared remarks, David, Brian and Eric will be available for Q&A. As noted in our earnings release, when describing our financial results, we use certain financial measures including adjusted income from operations and adjusted revenues, which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. A reconciliation of these measures to the most directly comparable GAAP measures, shareholders' net income and total revenues, respectively, is contained in today's earnings release, which is posted in the Investor Relations section of the cignagroup.com. We use the term labeled adjusted income from operations and adjusted earnings per share on the same basis as our principal measures of financial performance. In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2024 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. Pertaining to our financial results, in the fourth quarter, we recorded a net after-tax special item charge of $552 million or $1.88 per share. Details of the special items are included in our quarterly financial supplement. As described in today's release, special items are excluded from adjusted income from operations and adjusted revenues in our discussion of financial results. Additionally, please note that when we make prospective comments regarding financial performance, including our full year 2024 outlook, we will do so on a basis that includes the potential impact of future share repurchases and anticipated 2024 dividends. With that, I'll turn the call over to David.

Thanks, Ralph. Good morning, everyone, and thanks for joining our call today. 2023 was a very strong year for our company with consistent performance and sustained growth. We executed with discipline across our businesses. We delivered for our customers and patients, our employer clients, our health plan partners, and the others we serve. With our expertise and diverse breadth of capabilities, we continue to improve affordability and clinical outcomes as well as continue our work to expand access and choice. As we look forward, we're carrying momentum into 2024 and we expect another strong year of performance in growth. Now today, I'll focus my comments on key strategic drivers of our performance last year and how we continue to evolve and advance our business to sustain our impact on growth. Brian will then walk through additional details about our performance for 2023 as well as our outlook for 2024. Then we'll take your questions. Now before I go into our results, I want to comment on the announcement we made earlier this week; we reached a definitive agreement to sell our Medicare businesses to HCSC. We expect this transaction to close in early 2025, following customary legal and regulatory approvals. While we continue to see the seniors market as an attractive growth market, we concluded that our Medicare businesses, while large at about $12 billion in revenue, would require sustained investments and focus and capital as well as dedicated resources that were disproportionate with their size within the Cigna Group's portfolio. Additionally, with Evernorth's broad high-performing service portfolio, we will continue to serve the needs of seniors and grow our business. I would note that as part of our agreement, HCSC will be served by Evernorth for continued services for the customers we are selling. Additionally, we're expanding the reach of Evernorth's portfolio and see significant continued growth opportunities in Government services, including Medicare. Now as we consider the performance of our Medicare Advantage business in 2023, in the fourth quarter, results were in line with our expectations. For the year, we balanced high-quality and competitive benefits offerings, continued target market expansion, and disciplined pricing activity. Now with that, let's move into our 2023 headlines. Probably for 2023, we exceeded our financial commitments. Full year total revenue, we delivered $195.3 billion. Full year adjusted earnings per share was $25.09 and cash flow from operations of $11.8 billion. This performance extends our track record of delivering consistent positive results in the face of dynamic market conditions. It speaks to the power of our franchise and the purposeful way we've constructed our company, continuing to build on the strength of Cigna Healthcare while also shaping and expanding our Evernorth Health Services platform to lead the way in addressing evolving needs in the marketplace. As a result of our focus, discipline, and sustained execution, over the past decade, we've delivered adjusted EPS growth of more than 13% on an annualized basis. In the five years since our acquisition of Express Scripts, we've achieved or surpassed every goal we established for the combined company. Through 2023, we've grown revenue by over $50 billion and met or exceeded our adjusted EPS objectives each year. We've returned $27 billion to shareholders through share repurchases as well as attractive dividend payments. In 2023, after increasing our outlook for adjusted EPS twice over the course of the year, we had a strong finish and delivered full year adjusted EPS that was better than expectations. In short, we've demonstrated the ability to profitably evolve our business and services that we provide over many years, which enable us to continue to deliver on our commitments and growth. Now I'll discuss our performance in greater detail. I'll start with Evernorth. In our Express Scripts business, we successfully implemented the single largest contract ever in the pharmacy benefits industry. Throughout 2023, thousands of coworkers collaborated and worked with dedication, so we'd be ready to begin fulfilling well over 400 million annual prescriptions for 20 million Centene customers starting at the beginning of this year. Additionally, Centene was amongst hundreds of additional clients that were ready to be served in 2024, and I'm proud to say we're off to a strong start. The good work of our team has helped us meet the needs of our customers and reinforce the trust that Centene and other clients place in our company. Another Evernorth highlight for 2023 is that we once again advanced industry-leading innovation. Last spring, we launched a series of innovations, including ClearCareRx, to support affordability, additional transparency, and broader choice, as well as Independent Rx to partner and enable more closely with independent pharmacies. Then in November, we have further expanded choice for clients funding their pharmacy benefits with Express Scripts clear network. We were the first to launch a scaled pharmacy network model offering cost-based pricing. In addition, our accelerated growth businesses with Evernorth fueled our momentum as well. Accelerated growth in Accredo specialty pharmacy and CuraScript SD businesses and in our care services businesses contributed to Evernorth's strong top and bottom line results. With Accredo and CuraScript SD, we are supporting patients and providers with safe and effective use of the growing volume of high-cost clinically compliant specialty drugs. We also continue building out our care service platforms to ensure patients can access care when and how they need it, while also remaining connected with physical care. Our MDLIVE virtual platform, for example, is now available to over 60 million individuals as part of their benefits offering and is supporting the growing volume of care, including over 2.2 million virtual visits in 2023. Our results clearly demonstrate that with Evernorth's leading capabilities, we are a valued and flexible partner for health plans, employers, governmental organizations, and health care providers. In Cigna Healthcare, we drove revenue and customer growth through disciplined pricing and medical cost management. We serve employers and individuals who trust us to guide them through the health care system. Our leading clinical care programs continue to support our customers and patients, equipping them with the right information and insights they need to make the best choices for their health and vitality. Our ongoing pricing and continued progress in affordability initiatives in 2023 resulted in a medical care ratio that was better than expectations. Our U.S. Commercial Employer business had an outstanding year with continued strong growth. This was driven by our team's continued success in strengthening our competitive position through improved affordability and leveraging our high-performance networks and digitally enabled services as we expand care access, coordination of care, and overall value. Our individual exchange business performed broadly in line with our expectations for the fourth quarter. With the actions we've taken, we are on track to deliver improved profitability in 2024. In international health, we achieved another positive top and bottom line results. Our high-quality and localized health solutions, supported by our global provider network, continue to resonate very well with the globally mobile population and employees of multinational corporations as well as intergovernmental organizations. Now turning to 2024. We will sustain our growth in high performance by sharply focusing on the greatest opportunities with a well-balanced portfolio of complementary businesses and a clear durable strategic growth framework. First, we will drive continued steady predictable growth from our high-performing foundational growth businesses: pharmacy benefit, U.S. commercial employer, and our international health business. Our clients depend on our pharmacy services for example, and our expertise as well as our leadership in lowering costs for prescription drugs and addressing growing needs such as the high demand for the GLP-1 class of drugs for weight loss in diabetes. We have a long history of guiding appropriate access to medications and providing specialized clinical support, and we will continue to build on these efforts with new programs such as our EnCircleRx program. We're also supporting customers in additional ways, including by offering enhanced digital tools to help them better understand the value of their pharmacy benefits. We've been successful in growing our U.S. Commercial Employer business for more than a decade and continue to view this as a growth market for the Cigna Group. We continue to leverage the strength in coordinating a growing number of point solutions for our clients and improving clinical outcomes for our clients. Additionally, we continue to act as a disruptive innovator for small and middle-sized client needs. Second, we will build on further momentum for our accelerated growth portfolio, our fast-growing scaled specialty pharmacy business, and our care service businesses. We have tremendous opportunities in these large and expanding markets with our differentiated specialty capabilities, supporting patients with high-cost and clinically complex treatments. Within Care Services, we're advancing our capabilities in behavioral health, virtual and home care, as well as coordinated care programs for specific conditions. In summary, for 2024, we will grow our customer and revenue base again and our earnings and operating cash flow at the higher end of our long-term strategic targets. We've increased our expectations for full year 2024 adjusted EPS to at least $20.25, we expect our consolidated adjusted revenues to grow at least 20%, and we expect to generate at least $11 billion of operating cash flow. We will continue to return capital to our shareholders, including a 14% increase in our quarterly dividend. Now before I wrap it up and turn it over to Brian, I also wanted to mention the announcement we made last month about expanding roles for Brian and Eric. Brian has been our Chief Financial Officer for the past three years and will continue in that role. He will also expand his responsibilities as President and CEO of Cigna Healthcare. Eric is expanding his responsibilities as Executive Vice President of Enterprise Strategy for the Cigna Group, while also continuing as President and CEO of Evernorth Services. Brian and Eric's expanded positions, as well as other leadership changes we announced provide further clarity of our priorities and strategy, as well as the extent of reach and impact we expect to have. Importantly, it also reinforces the depth of our management bench. At our Investor Day on March 7 in New York City, you'll hear more from me, Brian, and Eric, as well as other key leaders from across our company. We look forward to sharing with you our views of the expanded addressable markets we see and how we've positioned the Cigna Group to advance our next chapters of attractive growth. Now I'll briefly summarize. With the momentum we carried out of 2023, we are raising our guidance for EPS in 2024. We are building on a strong year of disciplined execution, performance, and growth across our company. We deliver for our customers, clients, and partners. We kept our commitments to our shareholders, including delivering adjusted EPS for 2023 of $25.09, which was above our outlook, and we generated $11.8 billion of cash flow from operations. We have sharpened the focus of our portfolio further to ensure that we are positioned to drive another strong year for our company. We are building on a consistent track record of disciplined execution, innovation, and differentiated partnerships. We've increased our outlook for 2024 and now expect EPS of at least $28.25, and we will continue to advance the strategic deployment of capital, including using the majority of our discretionary cash flow for share repurchase in 2024. We'll have another strong year of performance, continue our track record for more than a decade of delivering against our 10% to 13% long-term adjusted EPS growth target, while maintaining an attractive dividend. And with that, I'll turn it over to Brian.

Thank you, David. Good morning, everyone. Today, I'll review the Cigna Group's fourth quarter and full year 2023 results and provide our outlook for full year 2024. We're proud to deliver another strong year for the Cigna Group, reflecting focused execution and growth across Evernorth and Cigna Healthcare. Looking at full year 2023, some key consolidated financial highlights include revenue of $195.3 billion, adjusted earnings per share of $25.09, and cash flow from operations of $11.8 billion, all well exceeding our initial expectations for the year. Fourth quarter enterprise results were particularly strong with revenue growing 12% to $51.1 billion, after-tax adjusted earnings growing to $2 billion, and adjusted earnings per share growing to $6.79. These results reflect broad-based strength across the company, and this momentum positions us well for growth in 2024. Regarding our growth platforms, I'll first comment on Evernorth. 2023 marked another year of sustained growth and profitability in Evernorth. As our market-leading clinical capabilities and innovative solutions continue to create differentiated value for our health plan, employer, and government clients and customers. Fourth quarter 2023 Evernorth revenues grew 12% to $40.5 billion, and pre-tax adjusted earnings grew 10% to $1.9 billion, both of which exceeded expectations. Evernorth's results in the quarter were driven by continued strong performance in our specialty pharmacy business, which saw double-digit year-over-year revenue growth to reach $60 billion in revenues for full year 2023. Our unwavering focus on reducing net costs for our clients as new drug innovations come to market, including GLP-1 agonists, biosimilars, specialty generics, and other emerging therapies for clinically complex conditions. The fourth quarter capped a strong 2023 for Evernorth with pre-tax adjusted earnings growing 5% for the year, above expectations. We achieved this even while incurring meaningful spending related to the implementation of our Centene relationship. Evernorth's favorable revenue and adjusted earnings growth in full year 2023 reflected strong execution and expansion across our foundational business, Express Scripts, and our scaled accelerated growth business, Accredo specialty pharmacy. Now turning to Cigna Healthcare. We outperformed expectations with full year 2023 pre-tax adjusted earnings growing 9%, reflecting another year of highly effective execution. Fourth quarter 2023 adjusted revenues were $13 billion and pre-tax adjusted earnings were $969 million, representing strong year-over-year growth. The medical care ratio was 82.2%, favorable to expectations. Our medical care ratio favorability was primarily driven by our U.S. Commercial Employer business, particularly within our stop-loss products, which outperformed expectations due to lower cost trends on high dollar claimants. Additionally, we saw lower-than-expected viral costs in the quarter with the combination of flu, COVID, and RSV running below projections. As David noted in his comments, we have entered a definitive agreement with HCSC to sell our Medicare businesses. We expect to close this transaction in early 2025, following regulatory approvals. Our full year 2024 outlook assumes full year contributions from our Medicare businesses. For the fourth quarter specifically, our Medicare Advantage business generated performance broadly in line with expectations. Across Cigna Healthcare, our full year 2023 medical care ratio was 81.3%, better than expectations, benefiting from our disciplined pricing execution, continued affordability initiatives, and the favorability in our Stop Loss products. The full year MCR of 81.3% was 70 basis points better than the midpoint of our initial 2023 guidance and is an improvement of 40 basis points from full year 2022. Moving to Cigna Healthcare medical customers, we ended 2023 with 19.8 million total medical customers, growth of approximately 1.8 million or 10% from year-end 2022, ahead of our initial guidance. This growth was driven by U.S. healthcare, primarily from U.S. commercial employer fee-based customers, as well as growth in individual exchange and Medicare Advantage. Cigna Healthcare continues to perform well with strong underlying fundamentals. Our results reflect the strength of our differentiated value proposition and focused execution across the business as well as the stability and consistency of the U.S. commercial employer market. Overall, we're very proud of our strong 2023 results in a disrupted market environment, reflecting the intentional design of the company's growth platforms and our ongoing disciplined execution. This provides us with considerable momentum for 2024 and beyond. Now turning to our outlook for full year 2024 specifically. We continue to expect strong underlying growth in Evernorth and Cigna Healthcare. We expect full year 2024 consolidated adjusted revenues of at least $235 billion, and we expect full year 2024 consolidated adjusted income from operations to be at least $8.025 billion or at least $28.25 per share, an increase from our prior outlook. When considering earnings seasonality, we would expect the adjusted earnings per share pattern to be similar to 2023. Now turning to our 2024 outlook for each of our growth platforms. At Evernorth, we expect full year 2024 adjusted earnings of at least $7 billion. We expect adjusted earnings within Evernorth to ramp as we move throughout the year with first quarter adjusted earnings contributing slightly below 20% of full year Evernorth adjusted earnings. The earnings ramp reflects the effect of early year client-specific onboarding spend. These investments are more concentrated in the first half of the year and taper off over the course of the year. For Cigna Healthcare, we expect full year 2024 adjusted earnings of at least $4.75 billion. Assumptions in our Cigna Healthcare outlook for 2024 include approximately 19.3 million total medical customers at year-end, and we expect our medical care ratio to be in the range of 81.7% to 82.7%, with the first quarter 2024 medical care ratio expected to be below the low end of the full year guidance range to reflect typical seasonal patterns. Additionally, for the Enterprise, we project an adjusted SG&A ratio of approximately 6.1% for 2024, reflecting a higher proportion of Enterprise revenue from Evernorth, which carries a lower SG&A ratio. We expect the consolidated adjusted tax rate to be in the range of 20.5% to 21%. Turning to our 2023 capital management position and 2024 capital outlook. We finished 2023 strong and delivered $11.8 billion of cash flow from operations. In 2023, we repurchased 7.8 million shares of common stock for approximately $2.3 billion, and we returned $1.5 billion to shareholders via dividends. Additionally, our debt-to-capital ratio finished the year at 40.1%, an improvement of approximately 100 basis points from year-end 2022. Now, framing our 2024 capital outlook, we expect to deliver at least $11 billion of cash flow from operations through our efficient service-based business model. We expect to deploy approximately $1.5 billion to capital expenditures. And we expect to deploy approximately $1.6 billion to shareholder dividends, reflecting our quarterly dividend of $1.40 per share, a 14% increase on a per-share basis. In 2024, we intend to use a majority of our discretionary cash flow for share repurchase. As we previously shared, we anticipate repurchasing at least $5 billion within the first half of 2024. Finally, we expect full year weighted average shares outstanding to be in the range of 282 million to 286 million shares. Now to recap, our full year 2023 consolidated results exceeded expectations, reflecting continued focused execution and discipline across Evernorth and Cigna Healthcare. Our 2024 outlook reflects continued strength and momentum across our two growth platforms, Evernorth and Cigna Healthcare. We are confident in our ability to deliver full year 2024 adjusted earnings of at least $28.25 per share. And with that, we'll turn it over to the operator for the Q&A portion of the call.

Our first question comes from A.J. Rice with UBS. You may ask your question.

Hi everybody and thanks for the question. Obviously, we have the announcement on your sale of the Medicare Advantage business. And yet you're saying you still view the business as attractive. Obviously, there's been some volatility in some of the performance of some of the other players in this space already announced. Is this the time in your mind to sort of step back from the market and give some time for the dust to settle? Or how should we interpret the comments that you still think that segment is attractive? And then also on that, obviously, there is speculation at least in the press about deal discussions. Your stock was quite volatile. I wonder if you could give us a little bit on how you approach large transactions, some of the financial parameters that people should keep in mind that would be hopefully reassuring for them.

Thank you. Good morning. It's David. You have a lot in that question. I appreciate it. Let me try to address some of the high points. First and foremost, we are really pleased with the nature of the transaction we're able to structure with HCSC. We see it as a win-win. It's a clarification to our strategy within our portfolio. While we view the market as an attractive growth market, the required capital investment resources focus relative to its size within our portfolio, coupled with the continued elevated regulatory environment, our decision was that it was best to enter this transaction. Second point is, very importantly, we've been quite deliberate now for several years, working to expand the service portfolio and the value proposition within Evernorth for health plan partners as it relates to their government services, be it Medicare, be it duals, or Medicaid, etc. We're demonstrating a very attractive proven track record of growing our government reach through the services franchise, and we will continue to fuel that on a go-forward basis and see that as an attractive trajectory for us. As it relates to your latter part of your question, I'll reframe our M&A criteria. I want to make sure I put that in the context of our capital deployment criteria. We continue to view, first, capital deployment priorities, investing in our business. Brian referenced the CapEx deployment of about $1.5 billion. Second, we always evaluate M&A for its appropriate attributes, which I'll come back to in a moment. And then third, returning capital to shareholders. As Brian noted, in 2024, in addition to raising our dividend by 14%, we expect to return the majority of our excess capital to shareholders through share repurchase with at least $5 billion in the first half of the year. Lastly, in your action-packed question, as we think about the criteria for transactions, we think about three criteria: first, strategic attraction; second, financial attraction; and then third, overall path to clarity. So is it strategically aligned? Is it financially attractive? As a final note, when we think about the financial piece of the equation, you evaluate each deal on its own respective merits but seeking to get high visibility in terms of your value creation for your organization if you're going to enter into a transaction. We're pleased with the decision and the transaction design. We will continue in a long-term service relationship with HCSC that further expands our proven track record within Evernorth. We see the Evernorth service portfolio as an attractive capital-light high visibility way to grow this portfolio. As we have in the past, we will maintain very strong discipline for capital deployment and our 2024 capital deployment priorities are quite clear. Thanks.

Thanks.

Thank you. Our next question comes from Stephen Baxter with Wells Fargo. You may ask your question.

Yes. Hi. Thanks. I just wanted to ask another kind of quick follow-up on the Medicare Advantage. So I would be curious if you'd be willing to share maybe your five- or 10-year view of the market. So I totally appreciate that it's a small part of your business before the sale. But you are still the eighth largest plan in the country. Do you think market share and concentration is ultimately going to look much more like the commercial market than it does today? Would love any kind of medium-term thoughts you could offer in the market. Thanks.

Steve, good morning, it's David. You're asking for a 10-year crystal ball. I think in the dynamism of the marketplace, most people come back to in terms of rolling three-year views of a given market. But stepping back, first and foremost, the Medicare Advantage offering, broadly speaking, in the marketplace is a very attractive offering for seniors. It has a long-term proven track record of delivering attractive benefits. Importantly, clinical coordination is essential when you get to the Medicare beneficiaries, typically dealing with a higher level of clinical burden that requires coordination. The care outcomes, the quality outcomes, the overall value outcomes are positive. Broadly speaking, from a societal standpoint, we see MA as an important asset for the U.S. to continue to be served, supported financially, and grow. Secondly, the marketplace will see ebbs and flows in terms of the funding mechanism. We see the early look at the rate letter at the moment in time; that's a moment in time, either acceleration or potentially deceleration for that marketplace. If you look at the senior satisfaction level, NPS broadly - Net Promoter Score is attractive for Medicare Advantage. Therefore, as I noted previously to A.J.'s point, we've worked aggressively to ensure that we have a broad and will continue to broaden the portfolio of services in support of health plans and integrated value-based care providers to be in support of value-based care, be it for Medicare Advantage tools or the commercial population. We see the marketplace as a growth market. Its respective growth will ebb and flow depending on government reimbursement to some level, lending toward benefit richness. The primary wave of the baby boomer aging has reached a peak and is slowing. It's still attractive, but that primary wave has reached its peak and is slowing somewhat. Take it as a whole; we see this as an expansion opportunity for Evernorth.

Thank you. Our next question comes from Lisa Gill with JPMorgan. You may ask your question.

Thanks very much, and good morning. I want to focus on Evernorth and maybe just understand some of the key drivers as we think about 2024. So first off, you talked about specialty in 2023. Can you talk about what your expectations are about growth in specialty in 2024? What you're doing around services? You touched a little bit on GLP-1. But you had a really big contract with CNC coming on board, but you also had an overall good 2024 selling season. So any of the key elements you can help us to understand as to what the drivers are for that strong AOI growth in Evernorth?

Thanks, Lisa. Good morning. It's Eric. A couple of different pieces in there. But first, let me just talk a bit about the portfolio of services that we're focused on in terms of Evernorth and transition that into some of the drivers of growth specifically for 2024. David noted in his prepared remarks a couple of highlights on capabilities we're growing. But I would call out, we are seeing significant interest from the market around teams helping to better coordinate individual point solutions and alleviate some of the burden that comes along with the fragmentation of how care is administered and how employers and plans are assembling care. So us working to improve navigation and reduce point solution fatigue is a key item. Second, I would note, behavioral care continues to be an area of focus, and there's meaningful opportunity for behavioral care to be better coordinated as there's significant comorbidities with individuals with mental health care needs, along with other care needs, and we're in a position to help address those challenges. The third item I'd note would be around specialty, and in particular, the opportunity for us to continue to grow as there are more therapies, more choices in the specialty market as well as navigating through biosimilars. Overall, we're positioned really well to continue to drive affordability and choice in biosimilars. As we've talked about previously, that's an important long-term multi-year tailwind in the economics and the growth of Evernorth overall. The continued growth in therapies like GLP-1s is a factor in our proposition overall. When you consider that suite of capabilities, that ends up being a really attractive portfolio that we've had continued growth in the number of lives we're serving, growth in our clients' lives that enables us to deliver the numbers that we're talking about. Overall, I'm really excited about the momentum we have going into 2024 and see ourselves well-positioned to deliver there and continue the trajectory beyond.

Thank you. Our next question comes from George Hill with Deutsche Bank. Your line is open. You may ask your question.

Yes. Good morning, guys. I guess just a couple of clarifying questions for me as it relates to MLR and the guide for '2024. You guys have bumped up the medical cost expectations. Can you kind of disaggregate what you're seeing by line of business there? And I just want to confirm that the MA business is still included in the continuing ops in the MLR guidance for 2024, because I saw in the footnotes, it's kind of being carried as an asset held for sale. So, just kind of like a disaggregation of kind of medical cost expectations and trend expectations for 2024.

Good morning, George, it's Brian. So let me just take the MA question first and then I'll get into the MCR. So as noted in my comments earlier, the Medicare Advantage business will continue to be reported through Cigna Healthcare through 2024. So all of our guidance, whether that be the revenue guidance, the customer volume guidance, the earnings guidance, all assume that the Medicare business will continue to be reported through Cigna Healthcare on an asset held-for-sale basis to clarify that. Within the MCR specifically, the midpoint of our guide obviously has a slight uptick from where we were in 2023. Now important to step back and thank the 2023 MCR performance was favorable to expectations and the primary driver of the Cigna Healthcare income outperformance. We're just really pleased with both quarter and full year coming in favorable to expectations. As I mentioned earlier, the 81.3% full year MCR was 70 basis points better than the midpoint of where we had started the guidance early in 2023. So you can think of the primary driver of the slightly higher projected 2024 MCR as being our stop-loss products within the U.S. Commercial Employer business. As I mentioned earlier, these ran favorable to our target profit margins in 2023. Our planning assumptions for the stop-loss products is normalizing back into their typical target profit margin range for 2024. Secondarily, there's some product mix shift within the Cigna Healthcare portfolio between 2023 and 2024 that will impact the overall Cigna Healthcare MCR, although I would note that we expect the overall Cigna Healthcare profit margin percentage to be higher in 2024 compared to 2023. We'd expect that to land near the low end of our targeted 9% to 10% range in 2024. Finally, when you think about our MCR guidance, as always, our guidance does have an appropriate level of prudence to start off the year.

Thank you.

Thank you. Our next question comes from Josh Raskin with Nephron Research. You may ask your question.

Hi. Thanks. Good morning. I wanted to get back to the Healthcare Services Corp. divestiture. Why was the PDP asset included in that sale? I would have thought that that would have had strategic value on the Evernorth side and that you have an advantage on the cost structure. Similarly, including Care Allies as well; was that more a tie-in to the Medicare Advantage business? And what does that mean for broad sort of value-based care network development at Cigna?

Good morning, Josh, it's David. Let me take a portion of your question and then ask Eric to expand. The statement is correct about the care allies; it was specifically focused on the MA portion of value-based care. Therefore, there's alignment there. Stepping back on value-based care, we have a long history and a proven track record of delivering very strong positive results for the benefit of our clients, patients, off of our value-based care orientation for commercial, for individual exchange, as well as for Medicare Advantage. As you know from our prior conversations, that's been a partner and enabled model as opposed to an owned model broadly speaking. In terms of owning the care delivery versus partnering enabling, additionally, I'd ask you to think about the commitment around that continuing. Our collaborative accountable care relationships for our commercial business and our exchange business continue on, as does our investment in and expansion of our Evernorth Accountable Care capabilities as we support healthcare delivery system partners around their value-based care. That continues, including our strategic partnership with Village. So on the value-based care side of the equation, there’s no change in strategy for us. This specific subset of our assets was solely aligned to the Medicare Advantage business. I'll ask Eric to talk about the direction relative to PDP and our multidimensional services relationship there. Eric?

Thanks, David, and good morning, Josh. Two things I would note for you here. First of all, as David and Brian had in their prepared remarks, we will have a multiyear services relationship between Evernorth and HCSC building on a relationship that already exists there. So Evernorth will have the opportunity to continue to provide services associated not only with the prescription drug element of this business but some of the other clinical coordination and related capabilities. We're excited about that opportunity to work together. Specifically to the employer PDP item, you should think of here as Express Scripts continuing to be the face of the employer offerings and this being seamless with all of our clients and services with the role that will be played around the insurance dynamics going to HCSC. This will be a set of relationships that Express Scripts and Evernorth will continue to manage from a relationship and account management perspective, and we'll continue to be very involved in areas that will be a focus for us. So overall, I'm very excited about the opportunity to continue to grow with another partner here.

Thank you. Our next question comes from Scott Fidel with Stephens. You may ask your question.

Hi. Thanks, good morning. Interested just now with the sale of the MA business, how your priorities for investment and for growth in Cigna Healthcare may change from that? You talked about how you've invested a lot in Medicare. So that should free up capital to invest in other businesses. So curious in terms of how you're thinking about where you can increase investment for growth in Cigna Healthcare, but also just how you're thinking about the exchange business now against the exit from MA, just around your overall risk business in Cigna Healthcare which will now be probably more weighted towards text, which is a pretty volatile business. So curious just on your thinking about the exchange business and sort of how you will view that business post the sale of MA? Thanks.

Scott, good morning, it's David. I think your umbrella tenant is right. So as I noted in my prepared remarks, the decision allows for sharpening of focus as we lean into our portfolio going forward. As you think about the investments, though, we have a long track record of making multiyear investments within our portfolio. Think about investments in a digital-first orientation and data-led capabilities continuing to invest in development of new programs and capabilities, be it what we talked about before with ClearCare or Pathwell capabilities, expanding the infrastructure and scale for a broader addressable market expansion and our proven CuraScript SD expansion as we face off and support a broadening array of healthcare professionals and integrated delivery systems. I mentioned to Josh the Evernorth Accountable Care capability. So think about, broadly speaking, our investment strategy continuing to fuel a variety of items and finally, sustained affordability, be it on the medical class pharmacy cost for administrative leverage that we get out of machine learning and AI through that lens. Regarding the question around the exchange or otherwise, we've always viewed the exchange business as sitting between commercial and government. Obviously, the government influences a meaningful portion of that through the benefit design and otherwise, yet we are able to successfully leverage our collaborative accountable care relationships. As we've demonstrated now for about a decade, with the exchange business, by taking a very targeted focus within that market from its inception in 2014 to today, we continue to see that as a complementary aspect to our business. We will take very targeted positions, market by market as long as we have the right collaborative care relationships in place; it has to be a complementary part of our portfolio. I don't see the exchange posture changing as a result of this. I don't think the investment strategy in the corporation changes as a result of it, it does create more capacity, though, as you articulated to accelerate in some of the categories I made reference to. I hope that helps, Scott.

Thank you.

Thank you. Our next question comes from Kevin Fischbeck with Bank of America. You may ask your question.

Great. Thanks. I was wondering if you could give a little more color about the membership guidance for 2024 by product. I know you're repricing exchanges, how is commercial going within commercial, the subsegments, and then a little more color on the Medicare Advantage volume expectations, and I guess that's in the guidance as well. Thanks.

Good morning, Kevin, it's Brian. As it relates to the net decline we have projected in the 2024 Cigna Healthcare customers, you can think of the primary driver of this being the individual exchange business. As we discussed late last year, we took some needed pricing actions in certain geographies in the individual exchange portfolio, and this will result in net customer declines for this business in 2024. Within the U.S. Commercial Employer business, we expect customer volumes to be up modestly. However, you should think of this by subsegment being split a bit. We expect to see a net decline in our national accounts business, but this will be more than offset by the continued strong growth within our Select segment. As a reminder, we continue to see opportunities for above-market growth in the Select segment, where our market share is still just 7%. When you think about the MA customer volume specifically, as we approach the 2024 bid cycle, as we always do, we apply a local market county level approach relative to how we price and set benefits. Therefore for most geographies, this resulted in stable benefits. In a few areas, we had some targeted pullbacks just in light of the funding environment in 2024. What we saw was in some of our local geographies; there was some very aggressive competitor behavior which resulted in less net growth than what we had originally expected for the Medicare Advantage business. Taken all together, we would expect to see net customer volumes down slightly for year-end 2024 in comparison to year-end 2023 within the Medicare Advantage space specifically. Overall, when you put all these pieces together, we're pleased with the overall balance in the Cigna Healthcare business right now as we expect to see profit margins expand year-over-year as I mentioned earlier, while serving a meaningful volume of customers that's grown markedly over the last two years.

Thank you. Our next question comes from Erin Wright with Morgan Stanley. You may ask your question.

Great. Thanks. On Evernorth, how are you thinking about the implications of cost-plus models and what that means at the PBM level and how does that influence your discussions with customers? Or just around your pharmacy network relationships? And just more broadly, just around transparency. Obviously, you talked about that in your prepared remarks in more transparent offerings at the PBM level and how do you think those offerings are gaining traction across your customer base? Thanks.

Hi Erin, it's Eric. First of all, just fundamentally, we start with the portfolio and approach that's equipped to offer choice and flexibility in how we work to support our clients, and so that's the lens I ground back to. We're always open to looking at new ways and approaches that drive increased affordability and meet the needs of our buyers. I'm really proud of the range of different financing solutions we offer and the number of innovations we've delivered in 2023 and already in 2024 in terms of the types of options that we bring to our clients. In fact, as David mentioned in the fourth quarter, we launched our clear network solution, which was its first of its kind. It's a comprehensive and simple solution to providing a cost index-based pharmacy network. The solution is unique in that it provides access to all the drugs in pricing based off of independent externally created cost on disease, kind of a simple margin that's shared between us and the dispensing pharmacy. Use that as an example. We had a lot of good conversations about that as a program and offering but would note that the selling seasons for these types of things tend to be long in time. So, there's a long lead time in terms of implementation. Clients are generally demanding more for their healthcare dollars and are looking for ways to improve affordability overall and broadly are not interested in paying more for the same services that they received today. We've got a wide variety of networks and solutions that exist already in the market and have the flexibility to adapt and adjust the configuration of our networks to trade-off costs relative to the value and access profiles that exist. Overall, we've got good flexibility, capabilities, and modularity to approach and align our capabilities with what our clients need.

Thank you. Our next question comes from Justin Lake with Wolfe Research. You may ask your question.

Thanks. Good morning. I wanted to ask a broader strategic question beyond MA. Most of your peers set up their business models over the last five to 10 years to manage a significant amount of their internal healthcare spend, right, and drive additional profitability and revenue from those services businesses. With the sale of MA, you're repricing your exchanges which makes sense, but your risk membership and the amount of medical costs you control, right, and are able to run through your services business just declines. How do you think about the value of those individual synergies of controlling medical costs and being able to provide services there, the natural growth it provides each and every year versus having to go out into the market and win each and every piece of business of growth, which obviously you've done pretty well over the last few years, but the stability of kind of having that internal membership? And how should investors expect this to impact your capital deployment strategy going forward? Thanks.

Justin, good morning, it's David. There's a lot in your question. Let me try to frame our thought process today and as we go forward. First, to date, we have a very clear proven track record of delivering a total cost, total quality, including clinical quality and service quality solution that resonates very well in the marketplace, whether it's in the benefit side of the equation or on the services side of the equation and our results reinforce that. Point two is we've executed a mix of partner and owned approach to delivery and fulfillment. We continue to evolve our portfolio. But philosophically, we do not believe that you have to own everything to be able to fulfill. If you reflect back on prior conversations within our portfolio at Investor Days, we framed the amount of services that Evernorth, for example, was fulfilling at a point in time for the Cigna Healthcare portfolio. We framed the expansion opportunity to your question and continue to expand those services. Our model, however, is also importantly not predicated on only having economic alignment for guaranteed cost. We're able to do it successfully under self-funded or shared funding mechanisms as well. We see the ability to continue to grow that over time with our Evernorth services portfolio. Point three is as it relates to services, we see additional step function opportunities to invest and continue to grow, especially in scale, specialty capabilities. The rate of spending growth and clinical complexity around that is off the charts. We have a leadership position there that will continue to grow, and we will continue to be market leaders in that space through our assets. Secondly, the need statements around behavioral health in the most comprehensive way; the market expects now a much more coordinated behavioral and physical health. We will continue to expand services that we have within our leading capabilities. Lastly, the breadth of virtual services, the ability to connect and coordinate and expand services as we go forward. We do agree with your point of continuing to invest in our services capabilities to support the right services but we do not believe you have to own all aspects of the care delivery equation to deliver that on a go-forward basis. We will spend time on this at our Investor Day on the seventh as it's an important part of our strategy today and growth strategy going forward.

Thank you. Our next question comes from Lance Wilkes with Bernstein. You may ask your question.

Great. Thanks. Could you talk a little bit about over in the Cigna Healthcare side of the business employer, how penetration rates are going with the specialty products in self-insured? And if there are any interesting trends as you go into 2024 here as you look at the selling season in 2025 with respect to that. And then as you've gone through the selling season, any changes in employer priorities? And then also just a quick clarification on if you could explain, there's a little drop in fees in the PBM. So that was just a clarification. The other one is a real question. Thanks.

Good morning, Lance, it's Brian. I'll take the majority of your question. I think there's a number of different pieces in there. As it relates to the specialty products, the attachment, if you will, to the medical in the Cigna Healthcare book of business has been a long-standing part of the company's strategy because we see the value of clinical integration being much greater when we have multiple components of relationship with an employer. This has been part of the company strategy for many years. It's important to bifurcate that by subsegment. In the down market, we call the Select segment under 500; most of those employers tend to buy the entirety of our offerings at once, so we have very high user work penetration rates in the under 500. Comparatively lower when you get to the national account space, where there tends to be a bit more a la carte purchasing of the different services. Broadly speaking, those patterns haven't changed too much over the last few years. On your question on the selling season, in particular and some employer preferences, the 2024 selling season is largely over with the exception of the Select segment. As mentioned earlier, that's an area for us that continues to grow at above-market rates, and we're really pleased with it. As we look forward to the 2025 selling season, we do have some national account RFPs in-house for both some existing clients and new business prospects. Directionally, RFP volumes are up a bit from prior years. These large clients tend to have unique needs. That said, there are a few areas that I would highlight as themes. Some of our larger employers are seeking to consolidate vendors or point solutions with those who can supply more integrated offerings, which we tend to call point solution fatigue. Another area is mental health and substance abuse benefits, which have become more important to employers for managing productivity and overall health of their employee base. Lastly, many larger employers are interested in digitally enabled care navigation capabilities to further optimize site of care and empower consumers at the time that care is delivered. Our Cigna Healthcare offerings are well-positioned to address these themes and the demand from large employers will simultaneously continue to grow share in the under 500 select segment. David wants to add a few comments.

Sure. Just to amplify and add one more thing; that point solution fatigue plays through in terms of opportunities for our Evernorth team as well as our Cigna Healthcare team. So around that, think about the ability to leverage solutions to get more value, better service, better clinical outcomes, overall value, and affordability. Secondly, I just wanted to reinforce a critical point when we think about penetration or cross-selling. Sometimes it's thought through and you didn't state this, but sometimes through under the notion of just cross-selling products. The integration of the products to deliver more value to the clients and customers is mission-critical. This shows up in better service quality, better clinical quality, and improved affordability. Our sustained differentiated MLR performance is, in many cases, aided by our proven ability to integrate certain services to come together with benefit the clients that enables us to generate a high level of cross-selling and a high level of penetration. Thanks, Lance.

Thank you. Our final question comes from Gary Taylor with TD Cowen. You may ask your question.

Hi. Good morning. David, I was hoping to ask an action-packed question like A.J. did, but I'm afraid I'm going to be too in the weeds for that. I just want to go back to stop-loss because it looks like a pretty substantial benefit to the 4Q and headwind. When I just look at how much your fourth quarter MLR outperformed your typical seasonal pattern, particularly in a quarter where there was broad trend acceleration? I try to square how much ACA enrollment and margin improvement should drive a tailwind, but 24 MLRs should actually decline year-over-year, but you're guiding it up. I mean it gets to hundreds and hundreds of basis points of variance around stop-loss. Could you quantify how much that helped 4Q and how much of a headwind that is for 24? And then the second part would just be, walk us through again why you had such favorable performance in that line?

Good morning Gary, it's Brian. As it relates to the stop-loss book, this is a really important part of the Cigna Healthcare portfolio, and we finished 2023 with $6 billion of premium in that product line. This book will naturally have some variability to it. So I wouldn't get overly fixated on one quarter's performance. There tends to be a little bit more settlement activity that transpires in the fourth quarter. So we had a little bit more favorability work its way through in the quarter, whereas if you smooth out over the course of the year, you don't see quite the same dynamic, which is one reason why when you bridge from 23 to 24, you shouldn't run rate the fourth quarter experience for that standpoint. The 90 basis points increase from where we landed at the end of 2023 to the midpoint of the 24% guide. A key component of that 90 basis points is an uptick we anticipate in the stop-loss product which is a function of our assumption to normalize back to usual levels of profitability on the stop-loss products. That's broadly the way to think about the dynamics at play with that product line.

Thank you. Our last question comes from Dave Windley with Jefferies. You may ask your question.

Hi. Thanks for squeezing me in. The premise of my question here is that your Evernorth profit guidance for 2024 looks pretty highly visible to us. So my questions underneath that are: one that you had guided 2023 to include a ramping contribution from biosimilars. How should we expect that to continue? Should that continue to ramp in magnitude? And then the second part was the significant onboarding costs for the Centene contract in 2023. Are you fully past those? Are those completely gone? Brian, you mentioned some Evernorth onboarding unrelated, but Evernorth onboarding. In your remarks, I just wanted to understand the relative size of those two items, please.

Good morning, it's David. Let me ask Brian to give you a framing in terms of the dynamics year-over-year. Brian can talk about that.

Overall, our AOI growth in Evernorth is expected to be about 9% as implied by the $7 billion or more of income we expect in the year. You can think of that as having the benefit of Centene-related costs now essentially normalizing back to a point where the profitability of that relationship is at breakeven. On top of that, we will have income performances more in line with our traditional algorithm of 5% to 7% average annual income growth. It reflects the benefit of all the multiyear trends that Eric talked about earlier, whether those be biosimilars, GLP-1 drugs, specialty generics, and other emerging therapies for clinically complex conditions. We are certainly seeing continued benefit from the biosimilar wave in 2024. As mentioned earlier, there's a specific and unique effect of the large volume we're receiving with the new client relationships in 2024. Eric can expand on that dynamic a bit.

Great. Thanks, Brian. With Centene, first, I would just start by actually noting how proud I am of how our team has delivered here and how we worked collaboratively across and with the Centene team. It's really been a great effort and one that's come together nicely for the benefit of our now shared customers. Implementation has gone well, and the first month has been quite successful. As consistent with what we've said before, in 2023, we had meaningful implementation spending and no associated revenue generated a loss 2024. We expect to achieve our run rate margin for this contract, which will be lower than the overall business. With respect to the year 2024 timing that Brian alluded to before, there's a lot more activity that has to happen at the beginning of a contract like this. More client outreach, work to get individuals into their therapies, etc. So there's a normal effect of additional work and activity that needs to take place in the first part of the year, and our expenses will reflect that. This is consistent with what we shared before. The final thing I'd note is consistent with our normal practice now that Centene is a live client of ours won't be commenting on specific profitability of a specific client or things along those lines, but the trajectory is off to the same start we expected consistent with what we talked about previously.

Thank you. I will now turn the call back over to David Cordani for closing remarks.

Thanks. Just a couple of messages to reiterate. First and foremost, 2023 was clearly a strong year of performance across our company as we executed quite well, reinforcing more than a decade of consistent execution and growth. We have confidence that we're going to sustain that momentum and leverage our well-balanced portfolio across our franchise and continue to deliver within our 10% to 13% long-term EPS growth range as well as pay an attractive dividend. I want to thank my coworkers around the world for their continued disciplined execution, their passion, importantly, in their caring orientation, and their dedication for those we serve. It shows up in our results. I'm really pleased and proud of what we delivered in 2023. I'm even more excited for our expansion of our reach and impact in 2024. As a final note, we look forward to seeing many of you at our Investor Day, which is a month away. In early March, we look forward to seeing you in New York City and our team will be excited to talk about the market expansion we see in front of us, our capabilities, and our opportunity to create additional value moving forward. Have a great day. Thanks.

Ladies and gentlemen, this concludes the Cigna Group's fourth quarter 2023 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 800-839-9317 or 203-369-3605. There is no passcode required for this replay. Thank you for participating. We will now disconnect.